AI across the RNA therapeutics lifecycle: discovery, development, and the road to personalized medicine
Jokūbas Leikauskas, Editor, Nucleic Acid Insights, speaks with Edward Miracco, Head of Enterprise AI Enablement, Moderna, about enterprise AI adoption, AI-driven lipid nanoparticle and neoantigen design, rare disease applications of mRNA, and the future of RNA therapeutics.
Authors
- Edward Miracco
Institutions
- Moderna Therapeutics (United States) (US)
Publication Details
- Journal
- Nucleic Acid Insights
- Published
- 2026-11-12
- DOI
- https://doi.org/10.18609/nai.2026.084
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00